Who invested in Engrail Therapeutics

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

$157Mraised across 1 round since 2024, from 2 sources

Latest round: Series B, $157MMar 2024
Investors: 5

See who backed them

The rounds

Mar 2024
Series B$157M
Source recorded and 1 other

Founders and team

From Engrail Therapeutics's own website: 4 on the team.

Paul CayerChief Financial Officer
Camilla GomieroVP, Commercial Strategy & Business Development
Peter BisgaardChairman of the Board
Saira RamasastryBoard Member

Everyone who backed them

Norwest Venture PartnersVC firm1round

Eight Roads VenturesVC firm1round

Forbion Capital PartnersPrivate equity1round

Foresite CapitalPrivate equity1round

Longwood FundVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Engrail Therapeutics

Who invested in Engrail Therapeutics?

Engrail Therapeutics's investors include Norwest Venture Partners, Eight Roads Ventures, Forbion Capital Partners, Foresite Capital and Longwood Fund.

How much has Engrail Therapeutics raised?

Engrail Therapeutics has raised $157M across 1 round since 2024.

When did Engrail Therapeutics last raise?

Engrail Therapeutics's most recent round was a Series B of $157M in Mar 2024.

What was Engrail Therapeutics's biggest round?

Its most recent round, $157M in Mar 2024, is also its largest on record.

Who backed Engrail Therapeutics first?

Engrail Therapeutics's first round on record, in Mar 2024, was backed by Norwest Venture Partners, Eight Roads Ventures and Forbion Capital Partners and 2 others.